TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: HOMA-IR (Homeostasis Model Assessment of Insulin Resistance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total fecal fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: fecal free fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of subjects with small bowel mucosal breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: itching alleviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of delivery at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: mean gestational age at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: incidence of recurrent preterm labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: mental component of QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: performance ratings
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: adherence ratings
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: classroom delivery ratings
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Estimated survival at 6 postoperative years
Endpoint domain: Mortality/survival
Primary endpoint: HbA1c-adjusted mean change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probability of achieving HbA1c <8.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probability of achieving HbA1c <7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hs-CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hCAP18 gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse or recurrence prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attenuation of reduction in PT in the upper esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GMP-140 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: t-PA improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PAI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anxiety and depression subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erection maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reducing morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improving the efficiency of health delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Graft failure within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: mood/apathy domain of the NMSS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mood score (Q1.3+Q1.4 of the MDS‐UPDRS Part 1)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: emotional well‐being domain of the PDQ‐39
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 12-month decrease in PDS PTSD scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 12-month decrease in SCL-20 depression scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 50% improvement in PTSD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 50% improvement in depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parents' comfort with talking to their adolescent about sex
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of sex‐ and HIV‐related topics discussed
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Parents' self‐efficacy for condom use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: urinary metabolite concentrations of dimethylthiophosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: probability of survival
Endpoint domain: Mortality/survival
Primary endpoint: Immediate recovery after propofol anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of propofol and sevoflurane
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Direct costs of anaesthesia treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: composite outcome of death, myocardial infarction, and repeat revascularization
Endpoint domain: Mortality/survival
Primary endpoint: incomplete revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Repeat operations
Endpoint domain: Adverse events/effects
Primary endpoint: Deep abdominal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistent HbA1c decrease of ≥0.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with antibody concentration >=0.2 microg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects with OPA titers >=8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Morphine consumption at 24 h
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-operative VAS-PI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative sedation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of intervention to reduce HIV transmission risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSGL-1 expression on neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: adherence to anti-tuberculous therapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: decrease of clinical and biochemical signs of hyperandrogenism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normalization of ovarian parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieved haemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRQLQ global score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma Zn levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Micronucleus frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Telomere base damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CESD scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical pregnancy rate per transfer
Endpoint domain: Mortality/survival
Primary endpoint: Esophageal acid exposure during running
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Activation timing of scapular muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Scapular upward rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knowledge of the illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target weight achievement at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average weight loss at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of new T2DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Grade 2 or 3 Musculoskeletal Toxicity (MST)
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of Gd-MRA in diagnosing >50% stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of Gd-MRA in diagnosing >50% stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean CIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean treatment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in RANTES concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in exhaled nitric oxide (F(ENO))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease in blood eosinophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean postoperative days of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean postoperative days of analgesic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-HBs titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PAI-1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Relative sensitivity of HPV test with cytology triage for CIN2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative sensitivity of HPV test with cytology triage for CIN3+
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of hrHPV test with cytology triage for CIN2+ and CIN3+
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function as measured by MoCA
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rates of canine movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of canine crown tip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Canine root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atopic eczema diagnosis
Endpoint domain: Adverse events/effects
Primary endpoint: Egg sensitisation
Endpoint domain: Adverse events/effects
Primary endpoint: success rate of medical treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first recurrence of sustained AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total AF burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of permanent AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients being pain-free at 12 months' follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increase in GLP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Negative behavior change at 2 weeks postoperatively
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean reduction of probing depth (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean attachment gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continence problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oswestry disability scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival of patients with relapsed or metastatic thyroid carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Peak serum GH response greater than 1 mU/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adult onset GH deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increment in IGF-I SDS after 6 months of GH replacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Recovery of viable BB-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Neurological examinations frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects associated with remifentanil
Endpoint domain: Adverse events/effects
Primary endpoint: intra-operative transfusion requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Weight-for-height z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body mass index-for-age z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Likelihood of abstinence at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of abstinence at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of abstinence at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child cognitive ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of hypotension before fetal extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lowest systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean FEV(1) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incremental costs of daily rhDNase
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bleeding index score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospitalisation for cardiovascular cause or death
Endpoint domain: Mortality/survival
Primary endpoint: Rate of acetabular erosion
Endpoint domain: Adverse events/effects
Primary endpoint: faster early recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: decreased sevoflurane consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of adequate endometrial aspiration specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0‐infinity) for intravenous ondansetron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of surfaces with bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pocket probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Skill improvement on the OSATS global rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative self-reported pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate-to-severe bowel distension
Endpoint domain: Adverse events/effects
Primary endpoint: Mobility of the joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adolescent intention to drink before 18 years old
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Device adherence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient rating of rehabilitation classes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Parental concern about traffic danger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: TNSMS (Total Nasal Symptom Mean Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pre‐ to post‐treatment improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: week-8 healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in CTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concurrent validity of MET values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test-retest reliability of heart rate responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in physical functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of the accuracy of fire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of medication withdrawal
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum voluntary contraction of the elbow flexor muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peak plasma creatine kinase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elbow joint angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: BMI Z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG delta power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of lid redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of lid roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of seroprotection 12 months after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in ICF (Intracortical Facilitation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in ICI (Intracortical Inhibition)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulmonary lactate release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete attachment of the retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: normal intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: perceptions of the birth experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correct ventilation pattern verification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentration of vancomycin in serum at 6h post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean excretion of vancomycin in urine over 5 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angina class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of admissions for angina
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Perfusion defects in the treated left ventricular free wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of subjects reaching LDL-C goal <110 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart failure event or death
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Poor lung function response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient preference for transdermal fentanyl
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mRNA and protein expressions of Smadl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Accuracy of prediction of resectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final infarction size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thirty-day composite end-point of death, recurrent MI or rehospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Walk speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma norepinephrine (NE) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Correct identification of S. mutans colonies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct identification of S. sobrinus colonies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bowel movement frequency per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes